Trial data for 2 Caribou CAR T-cell therapies due this year
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
Caribou Biosciences is reprioritizing its pipeline to focus on two of its CAR T-cell therapies for blood cancer, including one, CB-011, that’s being developed…
Simultaneously blocking the activity of two proteins, LSD1 and GSK3, may be an effective strategy to treat acute myeloid leukemia (AML), an aggressive type of…
Blood levels of the MUC5AC protein could help predict outcomes in people who have surgery for pancreatic ductal adenocarcinoma (PDA), the most common type of…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to the cell therapy BCB-276 as a potential treatment for diffuse intrinsic…
Offering genetic testing at the provider’s office at the time of diagnosis effectively increased the number of people with gynecological cancers who underwent testing. That’s…
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Blenrep (belantamab mafodotin) in combination with other medications for hard-to-treat multiple myeloma. The…
April 21 marks AML World Awareness Day — a global effort to boost recognition of acute myeloid leukemia (AML) and raise funds for research…
A combination of drugs to block two proteins, called PRMT5 and Chk1, may be effective for the treatment of pancreatic cancer, according to new…
The LY6H and GRM3 proteins could serve as potential biomarkers of glioma-related epilepsy (GRE), according to a study. Among people with gliomas, both proteins…
An experimental immunotherapy known as MOv18 IgE showed promise in overcoming the immune suppression caused by ovarian cancer cells, potentially enabling the immune system…